Quantcast

Latest Oncolytics Biotech Inc. Stories

2011-08-03 06:00:00

CALGARY, Aug. 3, 2011 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY), will present a corporate overview of the Company at the 31(st) Canaccord Genuity Growth Conference on Wednesday, August 10(th), 2011 at 3:00 p.m. ET. The conference will take place from August 9(th) to 11(th) at the InterContinental Hotel in Boston, MA. A live audio link to the webcast presentation will be available at: http://wsw.com/webcast/canaccord4/oncy/,...

2011-08-02 06:00:00

CALGARY, Aug. 2, 2011 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that an international team of researchers has reported on a study in the online version of Molecular Therapy, a publication of The American Society of Gene and Cell Therapy, investigating the timing of chemotherapy delivery that optimizes the efficacy of systemic REOLYSIN(®). The paper is entitled "Precise Scheduling of Chemotherapy Primes VEGF-producing...

2011-07-28 06:00:00

CALGARY, AB, July 28, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended June 30, 2011. "We continue to build upon and progress through our research and development in an effort to maximize the future commercial potential of REOLYSIN(®). In Q2, we focused our efforts on expanding our Phase III clinical trial in head and neck...

2011-07-06 06:00:00

CALGARY, July 6, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics") today announced that a presentation covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours was made today at the International Association for the Study of Lung Cancer World...

2011-07-05 06:00:00

CALGARY, July 5, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY) ("Oncolytics") today announced the appointment of George M. Gill, MD as Chief Medical Officer. He has been Senior Vice President of Clinical Safety and Regulatory Affairs and an officer of Oncolytics since 2002. "Dr. Gill has an outstanding track record, having supported the advancement of more than 20 products - including 11 anti-cancer agents - through the clinical research and regulatory...

2011-06-08 08:09:00

CALGARY, June 8, 2011 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC), (NASDAQ:ONCY) ("Oncolytics") today announced that an abstract covering interim preliminary results from a Phase 2 clinical trial using intravenous administration of REOLYSIN(® )in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours is available on the International Association for the Study of Lung Cancer World...

2011-06-02 06:00:00

CALGARY, June 2, 2011 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Jeffries 2011 Global Healthcare Conference on Thursday, June 9(th), 2011 at 10:00 a.m. ET. The conference will take place from June 6(th) to 9(th) in New York, NY. A live audio link to the webcast presentation is available at: http://www.wsw.com/webcast/jeff60/oncy/, or on the company's website at...

2011-05-12 21:27:00

CALGARY, May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") reports a correction of a formatting error in its first quarter news release issued on May 12, 2011.  The warrant liability line in the consolidated statement of financial position should read $nil, $5,536,800 and $1,023,051 for March 31, 2011, December 31, 2010, and January 1, 2010, respectively. The amounts reported in the total current liabilities line are...

2011-05-12 06:00:00

CALGARY, May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2011. "In order to maximize the future commercial potential for REOLYSIN(®), we continue to expand and advance our clinical program through a combination of our own trials and sponsored initiatives that allow us to cost effectively expand the scope of...

2011-05-11 06:30:00

CALGARY, May 11 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN(®), Oncolytics proprietary reovirus. Under the terms of the agreement, SAFC will perform process validation of the product, will continue to supply clinical requirements and will supply...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'